Short-term treatment using insulin-like growth factor-1 (IGF-1) improves life expectancy of the delta-sarcoglycan deficient hamster

Journal of Gene Medicine

Volumn 8, Issue 8, 2006, Pages 1048-1055

  Serose, Armelle ^a   Salmon, André ^a   Fiszman, Marc Y ^a   Fromes, Yves ^a,b,c  

^a INSERM   (France)

^b SAINT JOSEPH HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cardiomyopathy; Growth factor; Heart failure; IGF 1; Pathology; Survival

Indexed keywords

RECOMBINANT SOMATOMEDIN C; SARCOGLYCAN; SODIUM CHLORIDE; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DEATH; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HAMSTER; HEART FUNCTION; HISTOPATHOLOGY; LIFE EXPECTANCY; LONG TERM CARE; MALE; NONHUMAN; OSMOTIC PUMP; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; SHORT COURSE THERAPY; WILD TYPE;

ANIMALIA; CRICETINAE;

EID: 33747812666     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.934     Document Type: Article

References (26)

1. The Criteria Committee of the NYHA. Revision to Classification of Functional Capacity and Objective Assessment of Patients with Disease of the Heart. In Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels (9th edn). Brown & Co Ltd.: Boston, 1994; 253-256.
2. Hunter EG, Hughes V, White J. Cardiomyopathic hamsters, CHF 146 and CHF 147: a preliminary study. Can J Physiol Pharmacol 1984; 62: 1423-1428.
3. Sakamoto A, Ono K, Abe M, et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci U S A 1997; 94: 13873-13878.
4. Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 334: 809-814.
5. Duerr RL, Huang S, Miraliakbar HR, et al. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995; 95: 619-627.
6. Cittadini A, Isgaard J, Monti MG, et al. Growth hormone prolongs survival in experimental postinfarction heart failure. J Am Coll Cardiol 2003; 41: 2154-2163.
7. Welch S, Plank D, Witt S, et al. Cardiac-specific IGF-1 expression attenuates dilated cardiomyopathy in tropomodulin-overexpressing transgenic mice. Circ Res 2002; 90: 641-648.
8. Donath MY, Sutsch G, Yan XW, et al. Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. J Clin Endocrinol Metab 1998; 83: 3177-3183.
9. Donath MY, Froesch ER, Zapf J. Insulin-like growth factor I and cardiac performance in heart failure. Growth Horm IGF Res 1998; 8(Suppl B): 167-170.
10. McElhinney DB, Colan SD, Moran AM, et al. Recombinant human growth hormone treatment for dilated cardiomyopathy in children. Pediatrics 2004; 114: e452-458.
11. Anwar A, Gaspoz JM, Pampallona S, et al. Effect of congestive heart failure on the insulin-like growth factor-1 system. Am J Cardiol 2002; 90: 1402-1405.
12. Osterziel KJ, Strohm O, Schuler J, et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998; 351: 1233-1237.
13. Ren J, Samson WK, Sowers JR. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol 1999; 31: 2049-2061.
14. Serose A, Prudhon B, Salmon A, et al. Administration of insulin-like growth factor-1 (IGF-1) improves both structure and function of delta-sarcoglycan deficient cardiac muscle in the hamster. Basic Res Cardiol 2005; 100: 161-170.
15. Jin H, Yang R, Lu H, et al. Effects of early treatment with growth hormone on infarct size, survival, and cardiac gene expression after acute myocardial infarction. Growth Horm IGF Res 2002; 12: 208-215.
16. Chao W, Matsui T, Novikov MS, et al. Strategic advantages of insulin-like growth factor-I expression for cardioprotection. J Gene Med 2003; 5: 277-286.
17. Lee WL, Chen JW, Ting CT, et al. Insulin-like growth factor I improves cardiovascular function and suppresses apoptosis of cardiomyocytes in dilated cardiomyopathy. Endocrinology 1999; 140: 4831-4840.
18. Anker SD, Volterrani M, Pflaum CD, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol 2001; 38: 443-452.
19. Delaughter MC, Taffet GE, Fiorotto ML, et al. Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice. FASEB J 1999; 13: 1923-1929.
20. Marleau S, Lapointe N, Massicotte J, et al. Effect of chronic treatment with bovine recombinant growth hormone on cardiac dysfunction and lesion progression in UM-X7.1 cardiomyopathic hamsters. Endocrinology 2002; 143: 4846-4855.
21. Giudice PL, Gagnol JP, Bellucci A, et al. Autonomic nervous system activity imbalance in cardiomyopathic hamster. J Cardiovasc Pharmacol 2000; 36: 369-375.
22. Adamson PB, Smith AL, Abraham WT, et al. Continuous autonomic assessment in patients with symptomatic heart failure: prognostic value of heart rate variability measured by an implanted cardiac resynchronization device. Circulation 2004; 110: 2389-2394.
23. Ren J. Short-term administration of insulin-like growth factor I (IGF-1) does not induce myocardial IGF-1 resistance. Growth Horm IGF Res 2002; 12: 162-168.
24. Adams GR, McCue SA. Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. J Appl Physiol 1998; 84: 1716-1722.
25. Roubenoff R, Parise H, Payette HA, et al. Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med 2003; 115: 429-435.
26. Vasan RS, Sullivan LM, D'Agostino RB, et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med 2003; 139: 642-648.